AstraZeneca PLC (LON:AZN) Insider Tony Mok Purchases 1,500 Shares

AstraZeneca PLC (LON:AZN) insider Tony Mok bought 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average price of £126.80 ($160.45) per share, for a total transaction of £190,200 ($240,668.10).

AstraZeneca Price Performance

Shares of LON AZN opened at GBX 9,969 ($126.14) on Thursday. AstraZeneca PLC has a fifty-two week low of GBX 9,461 ($119.71) and a fifty-two week high of £133.88 ($169.40). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The firm has a market cap of £154.52 billion, a PE ratio of 3,164.76, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The business has a 50 day moving average price of £114.45 and a two-hundred day moving average price of £120.91.

Analyst Ratings Changes

AZN has been the subject of a number of research reports. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a £140 ($177.15) target price on shares of AstraZeneca in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £110 ($139.19) price target on shares of AstraZeneca in a research report on Tuesday, September 3rd. Finally, Berenberg Bank restated a “buy” rating and set a £150 ($189.80) target price on shares of AstraZeneca in a report on Monday, September 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of £104.12 ($131.75).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.